Biomedical subjects

H Terashima

Publications and source records attributed to H Terashima.

134 records · Page 8Linked to original sources

PubMedDate not supplied

Identification of neuropeptide-degrading enzymes in the pancreas.

Neutral endopeptidase (NEP) and aminopeptidase M (APM) were identified in the pancreas by enzymatic assays and Western blotting. The NEP activity, assessed by the phosphoramidon- and DL-thiorphan-inhibitable degradation of glutaryl-Ala-Ala-Phe-4-methoxy-2-naphthylamine, was 28.8 pmol/h/micrograms of pancreatic membrane protein and 124 pmol/h/10(6) pancreatic acinar cells. The APM enzymatic activity, assessed by the actinonin- and amastatin-inhibitable degradation of Ala-4-methoxy-2-naphthylamine, was 633 pmol/h/micrograms pancreatic membrane protein and 17.4 nmol/h/10(6) pancreatic acinar cells. Proteins corresponding to NEP (95 kDa) and APM (140 kDa) were identified in membranes by Western blotting. Both NEP and APM on acinar cells may degrade neuropeptides and regulate their effects on exocrine secretion.

Amino Acid Sequence↗

PubMedDate not supplied

Cystic lymphangioma of the gall-bladder: a case report.

Intra-abdominal cystic lymphangiomas are rare lesions that can be difficult to diagnose. We present a report of a patient with a giant multilocular cystic lesion in the abdomen. Ultrasonography and computed tomography scans of the abdomen revealed that the cyst had originated in the gall-bladder fossa. There was some calcification and thickening of the cyst wall. Endoscopic retrograde cholangiopancreatography demonstrated a medially deviated common bile duct, an elongated cystic duct and an inferior compressed gallbladder. There was no apparent communication between the cyst and the biliary tract; however, an abdominal angiogram revealed that the lesion was supplied by a branch of the cystic artery. Histological findings obtained intra-operatively were consistent with a cystic lymphangioma. Its characteristic histology was observed in the subserous layer of the gall-bladder. This case is a rare instance of a cystic lymphangioma originating in the gall-bladder.

Adult↗

PubMedDate not supplied

Apolipoprotein C-II modifications associated with an infusion of artificial lipid particles.

Artificial lipid particles used as parenteral nutrition solution do not contain any apolipoproteins when they are infused into the circulation. Despite the absence of apolipoproteins, the metabolism of artificial lipid particles is similar to that of chylomicrons which contain various kinds of apolipoprotein. Of the known apolipoproteins, apolipoprotein C-II (apo C-II) is important in the hydrolysis of triglyceride-rich lipoproteins via involvement in the activation of lipoprotein lipase. Modifications of apo C-II associated with intravenous infusion of a lipid emulsion were investigated in eight patients. Changes in apo C-IIs in high density lipoproteins (HDL), low density lipoproteins (LDL) and very low density lipoproteins (VLDL) together with the plasma level of triglycerides, were quantified before and for 90 min after a bolus injection of a 10% lipid emulsion (1 ml/kg of body weight). Immediately prior to the injection, 54% of the total amount of apo C-II was present in HDL, while 27% was present in VLDL. After 5 to 10 min, the amount of apo C-II in HDL decreased to 29% of the total, while that in VLDL increased to 62%. Subsequently, the amounts of apo C-II in HDL and VLDL began to return to the preinjection levels. These variations in apo C-II were closely correlated with the plasma clearance of triglyceride. The result indicates that the injected lipids are not inert particles during their short intravascular life, but that they acquire apo C-II from HDL.

Adult↗

PubMedDate not supplied

Pancoast tumour treated with combined radiotherapy and hyperthermia--a preliminary study.

Six patients with Pancoast (superior sulcus) tumours were treated with combined radiotherapy and hyperthermia from April 1986 to December 1989. Radiotherapy was performed using 10 MV X-ray, and all patients received total doses of 60-74 Gy, in five fractions per week, during 5.5-15 weeks. Hyperthermia was performed once or twice a week within 30 min after each irradiation, using 8 MHz RF capacitive heating equipment (Thermotron RF-8). Partial response, defined as 50% or more regression of the tumour, was observed in four of the six patients. Three patients are alive 30, 28, and 14 months after their treatments. Radiotherapy combined with hyperthermia appears to be a promising and effective means for treating Pancoast tumours.

Adenocarcinoma↗

PubMedDate not supplied

Relapsed non-Hodgkin's lymphoma: detection and treatment.

PURPOSE: To evaluate the optimal management strategy during clinical remission and after relapse in patients with non-Hodgkin's lymphoma (NHL). METHODS: Sixty-six patients with relapse of NHL from a state of clinical remission between 1987 and 1997 were analyzed retrospectively. The pattern of relapses, diagnostic methods used for relapses, and clinical outcome of salvage treatment were analyzed with attention to time after the achievement of clinical remission. RESULTS: Thirty-three relapses (50%) occurred within 12 months, and the remainder occurred gradually from 12-48 months after the first remission. Diagnosis of relapse in 61 of the 66 patients (93%) was made at unscheduled evaluations prompted by symptoms, on physical examinations, or because of high LDH levels. The 1- and 5-year cause-specific survival rates after relapse were 56.7% and 39.4%, respectively. The 1- and 5-year relapse-free survival rates were 50.1% and 35.0%, respectively. The 5-year relapse-free survival rate in patients with late relapse (49.5%) was significantly better than in those with early relapse (21.2%) (p<0.01). CONCLUSION: Time to relapse may be a useful factor to determine optimal management strategy in NHL patients.

Adult↗

PubMedDate not supplied

Radiotherapy for localized relapse in patients with non-Hodgkin's lymphoma: a preliminary report.

PURPOSE: To evaluate the usefulness of radiotherapy for relapse of non-Hodgkin's lymphoma (NHL) at a localized site. METHODS: Of 79 patients with relapsed intermediate- or high-grade NHL, 13 patients (16.5%) with a localized relapse were analyzed retrospectively. RESULTS: Five patients were treated with radiotherapy alone and eight were treated with radiotherapy plus conventional chemotherapy (CHOP or other combinations). Radiotherapy was delivered to the involved field to a mean total dose of 34.1 Gy (range, 21-51 Gy). The 5-year overall and disease-free survival rates were 80.2% and 76.2%, respectively. Four patients relapsed subsequently. After further salvage therapy, two patients died of NHL and two were alive without active disease. CONCLUSION: Radiotherapy may be an important component of treatment for selected patients with NHL who relapse at a localized site.

Antineoplastic Combined Chemotherapy Protocols↗

PubMedDate not supplied

MR imaging in uterine cervical cancer after radiotherapy.

The usefulness of MR imaging (MRI) in uterine cervical cancer after radiotherapy was evaluated in 18 patients. MRI was performed before and within one month after radiotherapy. In eight patients the uterus assumed a nearly normal appearance with resolution of the tumor on MRI. In another eight patients the tumors resolved, but an area of high signal intensity remained at the cervix. In these patients the tumors were well controlled at clinical examinations and during the mean follow-up period of 15-18 months. Therefore a persistent area of high signal intensity alone at the cervix on MRI is not itself indicative of residual tumor. An area of high signal intensity and a residual cervical mass persisted in two cases, and they were histologically proven to be due to residual tumor. Both patients died of recurrent disease at seven and 11 months after their radiotherapy. We conclude that MRI is useful for evaluating patients with cervical cancer at the completion of radiotherapy, and that MRI complements conventional clinical examinations.

Brachytherapy↗

PubMedDate not supplied

Radiotherapy of dural arteriovenous malformation in the cavernous sinus.

Six patients with dural arteriovenous malformation (DAVM) in the cavernous sinus were treated by irradiation. The region of the abnormal vascular network was irradiated with a 10 MV linear accelerator; the total dose given ranged from 3,200 to 5,100 cGy (150-200 cGy per day, 750-1,000 cGy per week). All patients responded favorably to the treatment, with three of the six having no residual symptoms or signs of disease. Postradiotherapy angiography confirmed the complete disappearance of the shunts in two of the three patients. No significant side effects were observed during the follow-up period, which ranged from 10 months to four years. Radiotherapy is considered to be a useful treatment method for DAVM, especially for those patients having shunts from the meningeal branches of the internal carotid artery.

Aged↗